Skip to content

Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.

Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality. - Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022974
Enrollment
64
Registered
2016-07-01
Start date
2016-07-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults feeling tired by work

Interventions

Oral ingestion of the test products containing 150mg mushroom mycelium powder (2 grains x 1 times per a day
12 weeks) Oral ingestion of the control products not containing mushroom emycelium powder (2 grains x 1 times per a day

Sponsors

RCT Japan Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [1]Japanese males and females aged 40-64 years [2]Individuals who are healthy and are not received treatment of disease [3]Individuals who feel tired by a physical labor [4]Individuals who serve a five-day work week (from Monday to Friday) and whose working hours are over 40 hours per a week [5]Individuals whose written informed consent has been obtained [6]Individuals who can come to the designated venue for this study and be inspected [7]Individuals judged appropriate for the study by the principal

Exclusion criteria

Exclusion criteria: [1]Individuals using medical products [2]Individuals who have a history of psychiatric disease, sleep disorder, high blood pressure, diabetes, and hyperlipidemia [3]Individuals who take medicine in the past 1 month to remedy disease [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease [5]Individuals who is a patient or have a history of or endocrine disease [6]Individuals whose BMI is over 30kg/m2 [7]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months [8]Individuals with serious anemia [9]Individuals who are sensitive to test product or other foods, and medical products [10]Individuals who are or are possibly, or are lactating [11]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day) [12]Individuals whose life style will change during the test period (ex. a night shift, travel for a long time, job transfer) [13]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 month or will ingest those foods during the test period [14]Individuals who participated in other clinical studies in the past 3 months [15]Individuals judged inappropriate for the study by the principal

Design outcomes

Primary

MeasureTime frame
[Fatigue and vitality] (1)CFS (Chalder's Fatigue Scale) (Week 0, 1, 4, 8, 12) (2)Japanese Edition of Profile of Mood States (Week 0, 1, 4, 8, 12) [Sleep] (1)Pittsburgh Sleep Quality Index, Japanese Version (Week 0, 4, 8, 12) (2)Obstructive Sleep Apnea Questionnaire (Week 0, 1)

Secondary

MeasureTime frame
[Antioxidant] (1)Diacron-Reactive Oxygen Metabolites test (Week 0, 1, 4, 8, 12) (2)Biological Antioxidant Potential test (Week 0, 1, 4, 8, 12) (3)Blood thiobarbituric acid reactive substances (Week 0, 1, 4, 8, 12) (4)Urinary isoprostane (Week 0, 4, 8, 12) (5)Urinary 8-OHdG (Week 0, 4, 8, 12) [Safety] (1)Blood pressure, pulsation (Week 0, 1, 4, 8, 12) (2)Weight, body fat percentage, BMI (Week 0, 1, 4, 8, 12) (3)Hematologic test (Week 0, 4, 8, 12) (4)Blood biochemical test (Week 0, 4, 8, 12) (5)Urine analysis (Week 0, 4, 8, 12) (6)Doctor's questions (Week 0, 1, 4, 8, 12) [Other] (1)Subject's diary (each day during the test period)

Countries

Japan

Contacts

Public ContactToshiyasu Tamura

TES Holdings Co., Ltd. Department of Clinical Trial

info@tes-h.co.jp03-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026